Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONC | CLUSTER | bearish | 5/10 | BeOne Medicines CEO John Oyler sold 4,139 shares and General Counsel Lee Chan Henry sold 664 shares, totaling $1.46M in | Jul 14, 2026 |
| LQDA | CLUSTER | neutral | 2/10 | Insider cluster at Liquidia Corp shows $3.16M in open-market sales by three insiders (Director Bloch, CCO Moomaw, CAO Bo | Jul 14, 2026 |
| ARTV | INSIDER-BUY | bullish | 5/10 | RA Capital Management, L.P., a director and 10% owner of Artiva Biotherapeutics, purchased 15,100 shares at $8.97 for a | Jul 14, 2026 |
| IRON | CLUSTER | neutral | 2/10 | Two insiders at Disc Medicine (CEO and COO) sold a combined $729K in open-market shares over a one-week window. The tota | Jul 14, 2026 |
| RNA | 8-K | bullish | 5/10 | Atrium Therapeutics announced FDA clearance of its IND application for ATR 1072, allowing the company to initiate the Co | Jul 14, 2026 |
| CBIO | 424B5 | bearish | 6/10 | Crescent Biopharma filed a preliminary prospectus supplement for an underwritten offering of ordinary shares and pre-fun | Jul 14, 2026 |
| CAPR | 8-K | neutral | 5/10 | Capricor Therapeutics entered into a lease for a new 171,000 sq ft headquarters in San Diego, with monthly base rent of | Jul 14, 2026 |
| PPCB | 8-K | neutral | 3/10 | Propanc Biopharma reported the retirement of independent director Annie Van Broekhoven and the appointment of Carlo Camp | Jul 14, 2026 |
| PLUR | 8-K | bearish | 7/10 | Pluri Inc. filed an 8-K updating the status of its €20 million EIB loan, which matured on June 1, 2026 and remains unpai | Jul 14, 2026 |
| ERAS | 8-K | mixed | 6/10 | Erasca priced an upsized public offering of 31,428,572 shares at $17.50 per share, raising approximately $516 million in | Jul 14, 2026 |
| ISPC | 8-K | neutral | 3/10 | iSpecimen Inc. completed Milestone 3 of its digital transformation program with SalesStack Solutions, making a $700,000 | Jul 14, 2026 |
| LLY | COURT-RULING | neutral | 3/10 | The Seventh Circuit reversed the district court's dismissal of Teva's breach of contract claim against Eli Lilly, allowi | Jul 14, 2026 |
| TEVA | COURT-RULING | bullish | 6/10 | The Seventh Circuit reversed the district court's dismissal of Teva's breach-of-contract claim against Eli Lilly, holdin | Jul 14, 2026 |
| ERAS | 424B5 | mixed | 6/10 | Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceed | Jul 14, 2026 |
| ANIK | 8-K | neutral | 3/10 | Anika Therapeutics entered into a Fifth Amendment to its existing credit agreement with Bank of America on July 10, 2026 | Jul 14, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K attaching a corporate presentation (Exhibit 99.1) and a Restricted Stock Unit Agreem | Jul 14, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Cytokinetics CEO Robert Blum exercised and sold 7,490 shares for ~$614K on July 13, and EVP R&D Fady Malik sold 3,500 sh | Jul 14, 2026 |
| ANNX | 144 | neutral | 2/10 | Former director Thomas G. Wiggans filed a Form 144 notice of intent to sell 1,000 common shares of Annexon (ANNX) with a | Jul 14, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K reporting that multiple PDMRs (including the CEO, CFO, and other senior executives) acquired ord | Jul 14, 2026 |
| GNPX | 8-K | bearish | 6/10 | Genprex filed a Certificate of Amendment for a 1:22 reverse stock split effective July 16, 2026, to regain compliance wi | Jul 14, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen announced Phase 2 CELIA data for diranersen, an anti-tau ASO, showing clinical slowing on CDR-SB (26% at 60 mg) a | Jul 14, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca signed an exclusive global license agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-sm | Jul 14, 2026 |
| APLM | 6-K | bullish | 5/10 | Apollomics Inc. regained compliance with Nasdaq's minimum Market Value of Listed Securities (MVLS) requirement, resolvin | Jul 14, 2026 |
| CANF | 6-K | bullish | 5/10 | Can-Fite BioPharma announced that the Australian Patent Office allowed a patent application covering Namodenoson for tre | Jul 14, 2026 |
| XOMA | 8-K | bullish | 8/10 | XOMA Royalty Corp. completed its acquisition by Ligand Pharmaceuticals on July 14, 2026. Common stockholders received $3 | Jul 14, 2026 |
| MESO | 6-K | bullish | 6/10 | Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestroce | Jul 14, 2026 |
| CRDL | 6-K | bullish | 5/10 | Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results for CardiolRx in recurrent pericard | Jul 14, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | Quantum Cyber announced a provisional patent filing for a modular drone launch system, but provided no financial details | Jul 14, 2026 |
| CING | 8-K | neutral | 3/10 | Cingulate Inc. filed an 8-K reporting the results of its 2026 Annual Meeting, where stockholders approved an amendment t | Jul 14, 2026 |
| IMUX | 8-K | neutral | 2/10 | Immunic filed an 8-K disclosing an updated corporate investor presentation on its website. The filing is a routine Regul | Jul 14, 2026 |